Form 4: Eli Lilly Director Katherine Baicker Acquires Shares in Recent Transaction

Director Katherine Baicker acquired shares of Eli Lilly & Co. common stock in a recent transaction.

Summary

• Katherine Baicker, a director at Eli Lilly & Co., acquired shares of the company's common stock.
• The transaction occurred on November 18, 2024.
• The director acquired 302.53 shares at a price of $727.2 per share.
• Following the transaction, Ms. Baicker beneficially owns 23,118.407 shares of Eli Lilly & Co.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as a director purchasing shares is generally seen as a good sign, but it's a routine transaction.

Positives

• A director's purchase of company stock can be seen as a positive signal of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider transactions.
• The transaction is typical for directors and officers of public companies, and the reporting is consistent with SEC regulations.
• Similar filings are made by directors and officers of other pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) when they trade their company's stock.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates

Keywords

insider trading, stock acquisition, director, share purchase, LLY, Eli Lilly